Bolivia Medical Device Grouping under Anexo 2: One Registration per Group

1. Key takeaways

Bolivia registers medical devices by group, one registration per group (Chapter 2 of the manual), with the grouping table set out in Anexo 2: devices are first assigned to one of three families — non-invasive, invasive, and active — and each family is then subdivided into numbered groups (for example, osteosynthesis implants and joint prostheses fall within the same invasive group). An addition to an existing registration can only be processed as a correction (rectificación), and the added items must belong to the same risk level and the same group as the original registration (Section 5.10.2). GRZAN’s assessment is that this rule makes catalogue mapping the first and most cost-determining step of any Bolivian project: any quotation or schedule issued before the mapping is complete cannot be relied upon.

The one-registration-per-group principle follows from how the registration fee is structured: each filed group is assessed as a distinct application, so the group count — not the model count — is what drives the official cost of a Bolivian project. This is why two product catalogues of identical commercial size can produce registration budgets that differ by a multiple, depending only on how SKUs distribute across the families of Anexo 2. The grouping decision also determines the shape of follow-on work: labels, instructions for use, and safety evidence must be organised so that every model inside a claimed group can be defended with the same dossier.

2. Legal basis

The mapping logic rests on two independent dimensions defined in the manual. Chapter 2 and Anexo 2 define the group dimension: which of the numbered groups across the three device families a product belongs to. Section 1.7 defines the risk dimension: the classification level assigned to the device. Section 5.10.2 then connects the two dimensions for changes to an existing registration, and the version in force on the AGEMED website must be confirmed before any grouping decision is finalised.

The three families of Anexo 2 are not arbitrary. Non-invasive devices, invasive devices, and active devices follow different evidence traditions, and the numbered groups inside each family collect products whose review questions tend to be similar. In practice, the family assignment is usually uncontroversial — the physical character of the device decides it — while the group assignment inside the family is where most mapping debates occur. GRZAN resolves these debates against the examples and wording of the manual itself rather than against marketing names, because AGEMED reviews against its own text, not against the manufacturer’s catalogue language.

3. Expert insights

Insight 1: one registration per group works in both directions. It means several models inside a single group may be covered by one registration — a cost opportunity — and it equally means products that cross groups cannot be covered by one registration — a cost trap. GRZAN approaches projects by looking at the opportunity first and the trap second: consolidate the SKU list into as few groups as possible, and only then evaluate whether the cross-group remainder justifies its own investment.

Insight 2: the addition restriction (same group, same level) sets the rhythm of catalogue expansion. Where a company plans to introduce its product line in phases, the group covered by the first registration determines whether later items can travel the low-cost correction path under Section 5.10.2. The first group selection should therefore be made against a 3 to 5 year product roadmap, not only against the first batch of SKUs.

Insight 3: grouping and risk classification are two separate dimensions. The group decides how many applications are needed; the level decides how deep the documentation must go. Where products at different risk levels appear inside what would otherwise be one group, a single registration cannot cover them — which is exactly why Section 5.10.2 requires the same group and the same level for any addition to an existing registration.

4. Practical recommendations

1. Produce a four-dimension mapping table of SKU, family, group, and risk level at project initiation, and treat it as the single baseline for quotations and schedules.
2. Let the first registration cover groups that span a 3 to 5 year roadmap, leaving room for later items to use the correction path.
3. Bring the mapping table under change management: re-run the mapping after each product iteration and judge whether a new application is triggered.

The mapping table also disciplines internal stakeholders. Sales teams can see, per SKU, which registrations cover them and which do not; regulatory teams can see which future launches will need a new group; finance can see how the registration count drives the fee budget. Without this single artefact, grouping decisions tend to be made per shipment under commercial pressure, which is the most expensive possible sequence.

For companies already registered elsewhere in Latin America, the mapping exercise has a shortcut worth noting: group boundaries in Bolivia frequently align with registration scopes obtained in other markets, and an existing regional registration structure can seed the Bolivian mapping table. The alignment is indicative only — Section 5.10.2 still governs any later addition, and the risk level must be restated under Section 1.7 — but starting from an existing scope shortens the mapping exercise from weeks to days and removes most of the guesswork from first-batch selection.

5. Verification checklist

• □ Confirm the mapping of all SKUs to the three families of Anexo 2 is complete
• □ Confirm the risk level of the products inside each group is consistent
• □ Confirm the groups covered by the first registration reflect the later product introduction plan
• □ Confirm additions can be handled through the Section 5.10.2 correction path
• □ Confirm the mapping table is embedded in the product change management process

GRZAN registration support. GRZAN provides medical device registration support in Bolivia for manufacturers, importers, and authorized representatives, including grouping analysis under Anexo 2, risk classification, and registration portfolio planning. For project inquiries, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.